RAPT Therapeutics (NASDAQ:RAPT) Stock

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Progressive - logo

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

EVER

RAPT

This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday

Equities

Financing

Contracts

Small Cap

Movers

RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment.

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

wall-street-4847634_1280

Eurozone

Commodities

Intraday Update

AILE

MGOL

RELI

TRAW

US Stocks Mixed, Dow Tumbles 150 Points

RAPT Therapeutics Inc

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT Therapeutics Announces $150 Million Private Placement

Management

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CTNM

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cargo Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Invivyd

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Macrogenics

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sutro Biopharma

Instil Bio

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Vor Biopharma

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Wells Fargo

Barclays

Leerink Partners

Comments

RAPT Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga